Compare
CDT Equity Inc. vs Earth Science Tech, Inc. vs Anixa Biosciences Inc vs Allarity Therapeutics, Inc.
| Latest fiscal year | CDT Equity Inc. CDT | Earth Science Tech, Inc. ETST | Anixa Biosciences Inc ANIX | Allarity Therapeutics, Inc. ALLR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-31 | 2025-10-31 | 2025-12-31 |
| Revenue | n/a | $35.70M | n/a | $320.0K |
| Revenue growth (YoY) | n/a | +7.8% | n/a | n/a |
| Gross margin | n/a | 71.4% | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | 10.2% | n/a | n/m |
| Net income | -$39.22M | $3.63M | -$10.93M | -$11.23M |
| EPS (Diluted) | -$1177.89 | $0.012 | -$0.34 | n/a |
| Operating cash flow | -$15.55M | $1.94M | -$7.17M | -$14.82M |
| Free cash flow | n/a | $1.18M | n/a | -$14.83M |
| Cash & equivalents | $1.51M | $796.8K | $1.24M | $14.69M |
| Total assets | $5.65M | $8.97M | $16.08M | $18.26M |
| Total liabilities | $12.82M | $1.93M | $2.13M | $8.43M |
| Shareholders' equity | -$7.17M | $7.01M | $15.16M | $9.83M |
| Return on year-end equity | n/a | 51.8% | -72.1% | -114.3% |
| Shares outstanding | 92.1K | 291.32M | 33.01M | 16.08M |
Revenue, most recent five fiscal years
| Fiscal year | CDT Equity Inc. | Earth Science Tech, Inc. | Anixa Biosciences Inc | Allarity Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $35.70M Ended 2026-03-31 | $210.0K Ended 2024-10-31 | $320.0K Ended 2025-12-31 |
| 1 year earlier | n/a | $33.12M Ended 2025-03-31 | $210.0K Ended 2023-10-31 | $0 Ended 2024-12-31 |
| 2 years earlier | n/a | $11.95M Ended 2024-03-31 | n/a | n/a |
| 3 years earlier | n/a | $48.5K Ended 2023-03-31 | $512.0K Ended 2021-10-31 | n/a |
| 4 years earlier | n/a | $14.1K Ended 2022-03-31 | n/a | n/a |